期刊
VACCINES
卷 10, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/vaccines10122064
关键词
cervical cancer; human papillomavirus; recombinant drugs; immunotherapy; therapeutic vaccine; plant-made pharmaceuticals
资金
- Chulalongkorn University, Thailand
Cervical cancer is a common gynecological malignant tumor, especially in developing countries, and it remains a major health problem. Despite research efforts, cervical cancer remains the leading cause of cancer death. Human papillomavirus (HPV) is the most important risk factor for cervical cancer. Early detection and immunotherapies show promise in improving survival rates, but high cost limits equal access to HPV vaccines. Developed countries have implemented screening programs and disease control systems, but low-income and middle-income countries see increasing incidence and limited access to affordable therapeutic options. Plant expression platforms offer a possible solution for producing affordable HPV vaccines.
Cervical cancer is the most common gynecological malignant tumor worldwide, and it remains a major health problem among women, especially in developing countries. Despite the significant research efforts employed for tumor prevention, cervical cancer ranks as the leading cause of cancer death. Human papillomavirus (HPV) is the most important risk factor for cervical cancer. Cervical cancer is a preventable disease, for which early detection could increase survival rates. Immunotherapies represent a promising approach in the treatment of cancer, and several potential candidates are in clinical trials, while some are available in the market. However, equal access to available HPV vaccines is limited due to their high cost, which remains a global challenge for cervical cancer prevention. The implementation of screening programs, disease control systems, and medical advancement in developed countries reduce the serious complications associated with the disease somewhat; however, the incidence and prevalence of cervical cancer in low-income and middle-income countries continues to gradually increase, making it the leading cause of mortality, largely due to the unaffordable and inaccessible anti-cancer therapeutic options. In recent years, plants have been considered as a cost-effective production system for the development of vaccines, therapeutics, and other biopharmaceuticals. Several proof-of-concept studies showed the possibility of producing recombinant biopharmaceuticals for cancer immunotherapy in a plant platform. This review summarizes the current knowledge and therapeutic options for the prevention of cervical cancer and discusses the potential of the plant expression platform to produce affordable HPV vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据